[Possibility of prevention of histamine-induced bronchospastic reaction with fenoterol, ipratropium bromide and lidocaine in patients with chronic bronchitis].
Kurgan
J
J
D000328:Adult; D000336:Aerosols; D000368:Aged; D001286:Atropine Derivatives / Q000627:therapeutic use*; D001986:Bronchial Spasm / Q000517:prevention & control*; D001991:Bronchitis / Q000188:drug therapy*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D005280:Fenoterol / Q000627:therapeutic use*; D006632:Histamine / Q000009:adverse effects*; D006633:Histamine Antagonists; D006801:Humans; D009241:Ipratropium / Q000627:therapeutic use*; D008012:Lidocaine / Q000627:therapeutic use*; D008875:Middle Aged
D000336:Aerosols; D001286:Atropine Derivatives; D004983:Ethanolamines; D006633:Histamine Antagonists; D005280:Fenoterol; D006632:Histamine; D008012:Lidocaine; D009241:Ipratropium
Mozliwość zapobiegania pohistaminowej reakcji skurczowej oskrzeli fenoterolem, bromkiem ipratropium i lidokaina u chorych na przewlekłe zapalenie oskrezeli.